Friday, December 3

The incidence rises two points to 53.77 cases

The incidence in Spain presents a new rise with 53.77 cases per 100,000 inhabitants, after on Thursday it exceeded the barrier of 50 cases and the country returned to the medium risk range of contagion of the coronavirus, according to Health criteria. The indicators of saturation in hospitals by COVID patients, however, remain stable and with a downward trend.



Children under 12 years of age, who have not yet entered the vaccination campaign, continue to report an increase in the incidence, which this Friday stands at 73.08 cases. On the other hand, people between 12 and 19 years of age continue to be the stratum with the lowest rate (29.34 cases). In addition, four age groups fall into the medium risk range of infection: people from 30 to 39 years old, those from 40 to 49, those from 60 to 69, and those from 70 to 79 years old.



The Ministry of Health has notified 3,093 new infections, a slight decrease compared to this Thursday, when it reported 3,291 cases. In total, 5,025,639 people have tested positive for coronavirus since the pandemic began.

Catalonia, with 534 new infections; Madrid, with 468; and Andalusia, which reports 418, are the regions that have reported the greatest increase in the number of coronavirus positives.



In addition, it has been known in this last day that 27 people have died, while on Thursday 15 deaths were reported by COVID-19. In total, 87,504 people have died since the start of the health emergency situation.

How is the epidemic evolving now?

Evolution of the cases and deaths reported, those hospitalized and those admitted to the ICU each day and the variation in the last 7 days

Source: Ministry of Health

Pfizer announces COVID-19 pill that reduces risk of death and hospitalization by 90%

The pharmaceutical company Pfizer today announced an experimental pill to treat the coronavirus that claims to reduce the risk of hospitalization and death by nearly 90 percent among people infected with the virus.

As reported by the US media, Pfizer has published this Friday the preliminary results of the study it conducted with this drug on a total of 775 adults.



www.eldiario.es

Leave a Reply

Your email address will not be published. Required fields are marked *